CYP1A1 is reported to metabolize compounds such as the antiarrhythmic drug amiodarone, antimicrobial erythromycin, antimalarial and immunomodulatory chloroquine (controversial in use against COVID-19 as an agent preventing the entry of SARS-CoV-2 through ACE2 receptor), nonsteroidal anti-inflammatory diclofenac, anti-psychotic haloperidol, steroid hormone estradiol and the chemotherapeutic agent daunorubicin in humans (Supplementary Table S2). This evidence concerns the gene CYP1A1 and COVID-19.